

Katrin Schaper-Gerhardt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4941740/publications.pdf>

Version: 2024-02-01

12
papers

174
citations

1307594

7
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

329
citing authors

#	ARTICLE	IF	CITATIONS
1	The H ₄ R is highly expressed on eosinophils from AD patients and IL-4 upregulates expression and function via the JAK/STAT pathway. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1261-1264.	5.7	9
2	Histamine downregulates the FCER1 chain expression in human IL-4-activated M2 macrophages. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1250-1254.	5.7	1
3	Expression of histamine receptors H2R and H4R are predominantly regulated via the IL-4/IL-13 receptor type II on human M2 macrophages. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2886-2890.	5.7	6
4	Sirolimus diminishes the expression of GRO-1 (CXCL-1) /CXCR2 axis in human keratinocytes and cutaneous squamous cell carcinoma cells. <i>Journal of Dermatological Science</i> , 2021, 104, 30-38.	1.9	1
5	Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells. <i>Frontiers in Immunology</i> , 2021, 12, 733961.	4.8	5
6	Histamine Increases Th2 Cytokine-Induced CCL18 Expression in Human M2 Macrophages. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11648.	4.1	11
7	The role of the histamine H ₄ receptor in atopic dermatitis and psoriasis. <i>British Journal of Pharmacology</i> , 2020, 177, 490-502.	5.4	51
8	Stimulation of histamine H ₄ receptors increases the production of IL-9 in Th9 polarized cells. <i>British Journal of Pharmacology</i> , 2020, 177, 614-622.	5.4	6
9	Histamine upregulates oncostatin M expression in human M1 macrophages. <i>British Journal of Pharmacology</i> , 2020, 177, 600-613.	5.4	18
10	Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. <i>European Journal of Cancer</i> , 2018, 93, 150-153.	2.8	43
11	PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. <i>European Journal of Cancer</i> , 2018, 88, 67-76.	2.8	15
12	The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes. <i>Journal of Dermatological Science</i> , 2018, 92, 172-180.	1.9	8